USFDA inspection at Unit II Valthera facility ends with minor procedural observation

Regulatory & Legal View source PDF Explain this filing

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.1%Reaction day

₹1458.80

prior close

₹1504.10

announcement price

In-mkt

timing

Nifty Smallcap 250market+1.5%+1.5% vs market

Pharmaceuticals peers, median of 172sector+0.6%+2.5% vs sector

On the reaction day the stock moved 1.5 pts more than Nifty Smallcap 250 and 2.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

-0.0

15m

-0.2

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.1+1.5+1.5+0.6+2.5

Next day

+7.6+1.5+6.1+1.1+6.5

+5.0+1.4+3.6+1.1+4.0

+7.1+2.2+4.9+2.0+5.1

+1.4+0.8+0.6+0.8+0.6

-0.4+0.8-1.2+0.6-1.0

-3.4-1.5-2.0+0.1-3.6

15d

-6.8-1.3-5.5-4.3-2.5

-11.7-3.2-8.5-5.9-5.8

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA inspected Concord Biotech's Unit II formulation facility at Valthera, Dholka, Gujarat on September 18, 2026. The inspection concluded with one minor procedural observation not related to GMP. The company will submit a response within the stipulated timeline and expects no material impact on business operations or existing supplies from this facility.

Likely market impact

Neutral to mildly positive. Only a minor procedural observation, no GMP issues. No material impact expected on business or supplies.